tetano
Editor, Senior Moderator
Clin Exp Med
. 2023 Jun 5.
doi: 10.1007/s10238-023-01095-0. Online ahead of print. Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study
Taraneh Arbabzadeh[SUP] 1 [/SUP], Maryam Masoumi Shahrbabak[SUP] 2 [/SUP], Parichehr Pooransari[SUP] 1 [/SUP], Mahdi Khatuni[SUP] 3 [/SUP], Masoumeh Mirzamoradi[SUP] 1 [/SUP], Soraya Saleh Gargari[SUP] 4 [/SUP], Zahra Naeiji[SUP] 4 [/SUP], Nayereh Rahmati[SUP] 4 [/SUP], Samaneh Omidi[SUP] 1 [/SUP], Faridadin Ebrahimi Meimand[SUP] 5 [/SUP]
Affiliations
Data on the efficacy of remdesivir in Coronavirus Disease 2019 (COVID-19) are limited in pregnant patients since they have been excluded from clinical trials. We aimed to investigate some clinical outcomes following remdesivir administration in pregnancy. This was a retrospective cohort study conducted on pregnant women with moderate to severe COVID-19. The enrolled patients were divided into two groups with and without remdesivir treatment. The primary outcomes of this study were the length of hospital and intensive care unit stay; respiratory parameters of hospital day 7 including respiratory rate, oxygen saturation, and mode of oxygen support; discharge until days 7 and 14, and need for home oxygen therapy. Secondary outcomes included some maternal and neonatal consequences. Eighty-one pregnant women (57 in the remdesivir group and 24 in the non-remdesivir group) were included. The two study groups were comparable according to the baseline demographic and clinical characteristics. Of the respiratory outcomes, remdesivir was significantly associated with a reduced length of hospital stay (p = 0.021) and also with a lower level of oxygen requirement in patients on low-flow oxygen [odds ratio (OR) 3.669]. Among the maternal consequences, no patients in the remdesivir group developed preeclampsia but three patients (12.5%) experienced this complication in the non-remdesivir group (p = 0.024). Furthermore, in patients with moderate COVID-19, the percentage of emergency termination was significantly lower in remdesivir group (OR 2.46). Our results demonstrated some probable benefits of remdesivir in respiratory and also maternal outcomes. Further investigations with a larger sample size should confirm these results.
Keywords: COVID-19; Preeclampsia; Pregnancy; Remdesivir; Respiratory parameters.
. 2023 Jun 5.
doi: 10.1007/s10238-023-01095-0. Online ahead of print. Remdesivir in pregnant women with moderate to severe coronavirus disease 2019 (COVID-19): a retrospective cohort study
Taraneh Arbabzadeh[SUP] 1 [/SUP], Maryam Masoumi Shahrbabak[SUP] 2 [/SUP], Parichehr Pooransari[SUP] 1 [/SUP], Mahdi Khatuni[SUP] 3 [/SUP], Masoumeh Mirzamoradi[SUP] 1 [/SUP], Soraya Saleh Gargari[SUP] 4 [/SUP], Zahra Naeiji[SUP] 4 [/SUP], Nayereh Rahmati[SUP] 4 [/SUP], Samaneh Omidi[SUP] 1 [/SUP], Faridadin Ebrahimi Meimand[SUP] 5 [/SUP]
Affiliations
- PMID: 37277553
- DOI: 10.1007/s10238-023-01095-0
Data on the efficacy of remdesivir in Coronavirus Disease 2019 (COVID-19) are limited in pregnant patients since they have been excluded from clinical trials. We aimed to investigate some clinical outcomes following remdesivir administration in pregnancy. This was a retrospective cohort study conducted on pregnant women with moderate to severe COVID-19. The enrolled patients were divided into two groups with and without remdesivir treatment. The primary outcomes of this study were the length of hospital and intensive care unit stay; respiratory parameters of hospital day 7 including respiratory rate, oxygen saturation, and mode of oxygen support; discharge until days 7 and 14, and need for home oxygen therapy. Secondary outcomes included some maternal and neonatal consequences. Eighty-one pregnant women (57 in the remdesivir group and 24 in the non-remdesivir group) were included. The two study groups were comparable according to the baseline demographic and clinical characteristics. Of the respiratory outcomes, remdesivir was significantly associated with a reduced length of hospital stay (p = 0.021) and also with a lower level of oxygen requirement in patients on low-flow oxygen [odds ratio (OR) 3.669]. Among the maternal consequences, no patients in the remdesivir group developed preeclampsia but three patients (12.5%) experienced this complication in the non-remdesivir group (p = 0.024). Furthermore, in patients with moderate COVID-19, the percentage of emergency termination was significantly lower in remdesivir group (OR 2.46). Our results demonstrated some probable benefits of remdesivir in respiratory and also maternal outcomes. Further investigations with a larger sample size should confirm these results.
Keywords: COVID-19; Preeclampsia; Pregnancy; Remdesivir; Respiratory parameters.